Observation of Patient and Caregiver Burden Associated with Early Alzheimer’s Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study

Manuscript Number: 

19-0430R2

Author(s): 
Jeffrey Scott Andrews, Valerie Bruemmer, Howard Fillit, Yongin Kim, Dorene M. Rentz, Rebecca L. Robinson, Ronald L. Schwartz, Wenyu Ye, Anthony Zagar

Disclosures

Jeffrey Scott Andrews

  • Equity:
    Minor shareholder of Eli Lilly and Company
    Sponsors:
    Employee of Eli Lilly and Company

Valerie Bruemmer

  • Equity:
    Eli Lilly employee/ stock/ stock options
    Sponsors:
    Full time employee

Howard Fillit

  • Consulting Fees:
    VTV, Samus, Axovant, Genentech, Otsuka, RTI, Merck.

Yongin Kim

  • Equity:
    minor stock owner
    Sponsors:
    an employee of sponsor

Dorene M. Rentz

  • Consulting Fees:
    Consulting fees to Biogen and Eli Lilly Advisory Board: Neurotrack

Rebecca L. Robinson

  • Equity:
    Employee and minor stockholder of Eli Lilly and Company.
    Sponsors:
    Employee and minor stockholder of Eli Lilly and Company.

Ronald L. Schwartz

  • Patents/Royalties
    Clinical research support from Eli Lilly and Company, Abbvie, Biogen, Eisai, Genentech, Novartis, Janssen, vTv, Neurim.

Wenyu Ye

  • Equity:
    employee of Eli Lilly and company and received company's stock
    Sponsors:
    I am employed by Eli Lilly and company that sponsored the study

Anthony Zagar

  • Equity:
    Employee of Eli Lilly and Company. Stock is granted as company contribution to 401K plan.
    Sponsors:
    Statistical Scientist